8-K: Calidi Biotherapeutics Reports Full-Year 2023 Results and Advances in Immunotherapy Programs

Calidi Biotherapeutics announced its fourth quarter and full-year 2023 financial results, highlighting progress in its clinical programs and the development of new immunotherapy platforms.

Summary

• Calidi Biotherapeutics reported a net loss of $8.2 million for the fourth quarter of 2023, compared to a $7.8 million loss in the same period of 2022.
• The company's full-year 2023 net loss was $29.2 million, an increase from the $25.4 million loss in 2022.
• Research and development expenses increased to $4.0 million in Q4 2023 and $13.0 million for the full year, up from $2.3 million and $7.3 million respectively in 2022.
• General and administrative expenses were $5.9 million for Q4 2023 and $16.0 million for the full year, compared to $2.4 million and $15.9 million respectively in 2022.
• Calidi had approximately $1.9 million in cash and $0.2 million in restricted cash as of December 31, 2023.
• The company is developing novel systemic enveloped oncolytic virotherapy platform, RTNova, designed to target diverse tumor types.
• Calidi anticipates reporting an interim clinical update from its Phase 1 trial evaluating CLD-101 in high-grade glioma patients in the second quarter of 2024, assuming successful capital raising.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in research and development, the increased losses and low cash position are concerning. The need for additional capital is a significant risk.

Positives

• City of Hope received a $5.3 million grant to advance Calidi's CLD-101 program for ovarian cancer.
• The development of the RTNova platform expands Calidi's potential to treat a wider range of solid tumors.
• The addition of experienced members to the Scientific and Medical Advisory Board and Board of Directors enhances the company's expertise.
• The new patent for the SuperNova technology platform strengthens Calidi's intellectual property portfolio.
• Calidi is planning to initiate a clinical trial for SuperNova in the second half of 2024.

Negatives

• The company experienced increased net losses in both the fourth quarter and full year of 2023 compared to 2022.
• Research and development expenses and general and administrative expenses increased significantly in 2023.
• Calidi had only $1.9 million in cash at the end of 2023, which may necessitate further capital raising.
• The company's ability to report an interim clinical update in the second quarter of 2024 is contingent on raising additional capital.

Risks

• Calidi's ability to continue its clinical trials is dependent on securing additional capital.
• Early clinical trial results may not be indicative of final outcomes.
• There is a risk that Calidi may not receive FDA approval for its therapeutic candidates.
• The company faces risks related to the development and commercialization of its technologies.
• The company's financial position is weak with only $1.9 million in cash.

Future Outlook

Calidi anticipates reporting an interim clinical update from its Phase 1 trial evaluating CLD-101 in high-grade glioma patients in the second quarter of 2024, assuming successful capital raising, and plans to initiate a clinical trial for SuperNova in the second half of 2024.

Management Comments

• Calidi continues to make great progress across our development programs while continuing to innovate and expand our industry-leading position in cell-based immunotherapies, said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
• We anticipate reporting an interim clinical update from our Phase 1 trial evaluating CLD-101 in high-grade glioma patients in collaboration with City of Hope in the second quarter of this year assuming we are successful in raising additional capital.

Industry Context

The announcement highlights Calidi's efforts in the competitive immuno-oncology space, where companies are developing novel therapies to target cancer. The collaboration with City of Hope and the development of new platforms like RTNova and SuperNova position Calidi as an innovator in the field.

Comparison to Industry Standards

• Calidi's increased R&D spending is typical for a clinical-stage biotech company, as they invest heavily in developing their pipeline.
• The net losses are also common for companies at this stage, as they are not yet generating significant revenue.
• The $5.3 million grant from CIRM is a significant achievement, as it provides non-dilutive funding for the development of CLD-101.
• The appointment of experienced members to the Scientific and Medical Advisory Board and Board of Directors is a positive sign, as it demonstrates the company's commitment to building a strong team.
• The development of novel platforms like RTNova and SuperNova is a key differentiator for Calidi, as it allows them to target a wider range of cancers.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased losses and the need for additional capital.
• Employees may be impacted by the company's financial situation and future plans.
• Customers (patients) may benefit from the development of new therapies.
• Suppliers and creditors may be impacted by the company's financial situation.

Next Steps

• Calidi plans to report an interim clinical update from its Phase 1 trial evaluating CLD-101 in high-grade glioma patients in the second quarter of 2024.
• The company plans to dose the first patient in the CLD-101 Phase 1 trial in collaboration with Northwestern University in the first half of 2024.
• Calidi plans to dose the first patient in the CLD-201 Phase 1 trial in the second half of 2024.

Key Dates

Keywords

immunotherapy, oncolytic virotherapy, cancer, clinical trials, biotechnology, stem cells, NeuroNova, RTNova, SuperNova, CLD-101, CLD-201, CLD-400